Phio Pharmaceuticals (PHIO) Price & Analysis

Compare

579 Followers

PHIO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.97 - $9.79

Previous CloseN/A

Volume62.29K

Average Volume (3M)1.83M

Market Cap

$11.68M

Enterprise Value$492.91K

Total Cash (Recent Filing)$10.78M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta2.41

Next Earnings

Nov 06, 2025

EPS Estimate

-0.46

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.45

Shares Outstanding5,726,750

10 Day Avg. Volume146,181

30 Day Avg. Volume1,831,049

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.04

Enterprise Value/Revenue7.04

Enterprise Value/Gross Profit-0.81

Enterprise Value/Ebitda-0.07

Forecast

1Y Price Target

$14.00

Price Target Upside589.66% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe safety monitoring committee recommends advancing PH-762 to final cohorts, indicating a clean safety profile and potential for first in class product status.

Market PotentialThe stock is considered undervalued with significant potential upside, driven by PH-762's promising trial results and the company's strategic positioning.

Strategic PositioningPhio Pharmaceuticals maintains business development optionality as it advances its portfolio of conditionally active siRNA therapies, positioning itself well for potential partnerships.

Bears Say

Clinical RisksFactors that could impede reaching the price target include failed or inconclusive clinical trials and the inability to secure adequate funding.

Market CompetitionDespite the crowded skin cancer therapy market, there is a high unmet need due to the tumor's high incidence, less than optimal efficacy of available treatment options, and drug resistance to systemic therapies.

Phio Pharmaceuticals News

Phio Pharmaceuticals files to sell 1.93M shares of common stock for holders

06:08 EDT Phio Pharmaceuticals (PHIO) files to sell 1.93M shares of common stock for holders Published first on...

13d ago

PHIO

Phio Pharmaceuticals Issues New Warrants for $2.5M

Phio Pharmaceuticals ( ($PHIO) ) just unveiled an update. On July 25, 2025, Phio Pharmaceuticals Corp. entered into...

29d ago

PHIO

Phio Pharmaceuticals Announces New Manufacturing Agreement

Phio Pharmaceuticals ( ($PHIO) ) just unveiled an announcement. On July 25, 2025, Phio Pharmaceuticals announced a new...

1M ago

PHIO

Phio Pharmaceuticals Announces 2025 Annual Meeting Details

Phio Pharmaceuticals ( ($PHIO) ) just unveiled an announcement. Phio Pharmaceuticals Corp. has announced that its 2025 Annual...

2M ago

PHIO

Phio Pharmaceuticals Advances in PH-762 Clinical Trial

The latest announcement is out from Phio Pharmaceuticals ( ($PHIO) ). On June 25, 2025, Phio Pharmaceuticals announced...

2M ago

PHIO

Phio Pharmaceuticals’ PH-762: Promising Clinical Progress and Strategic Potential Drive Buy Rating

Analyst Matthew Keller from H.C. Wainwright reiterated a Buy rating on Phio Pharmaceuticals (PHIO – Research Report) and...

2M ago

PHIO

Phio Pharmaceuticals Announces Strategic Initiative and Leadership Changes

An update from Phio Pharmaceuticals ( ($PHIO) ) is now available. On June 6, 2025, Phio Pharmaceuticals announced...

3M ago

PHIO

Phio Pharmaceuticals: Undervalued Innovator with Promising siRNA Therapy and Strategic Growth Potential

Matthew Keller, an analyst from H.C. Wainwright, has initiated a new Buy rating on Phio Pharmaceuticals (PHIO). Matthew...

3M ago

PHIO

Phio Pharmaceuticals assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Phio Pharmaceuticals (PHIO) with a Buy rating and $14 price target Phio’s lead...

3M ago

PHIO

Phio Pharmaceuticals Reports Positive Phase 1b Trial Results

The latest update is out from Phio Pharmaceuticals ( ($PHIO) ). On May 7, 2025, Phio Pharmaceuticals announced...

4M ago

PHIO

3 Penny Stocks to Watch Now, 4/10/25

Phio Pharmaceuticals, Antelope Enterprise Holdings, and iCoreConnect are the 3 Penny Stocks to watch on April 10, 2025, based on TipRanks’...

5M ago

AEHL

ICCT

Phio Pharmaceuticals Appoints David Deming to Board

An update from Phio Pharmaceuticals ( ($PHIO) ) is now available. Phio Pharmaceuticals Corp. announced the appointment of...

6M ago

PHIO

Phio Pharmaceuticals files to sell 5.93M shares of common stock for holders

16:41 EST Phio Pharmaceuticals (PHIO) files to sell 5.93M shares of common stock for holders Published first on...

7M ago

PHIO

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

7M ago

AZTR

BDTX

PHIO FAQ

What was Phio Pharmaceuticals’s price range in the past 12 months?

Phio Pharmaceuticals lowest stock price was $0.96 and its highest was $9.79 in the past 12 months.

What is Phio Pharmaceuticals’s market cap?

Phio Pharmaceuticals’s market cap is $11.68M.

When is Phio Pharmaceuticals’s upcoming earnings report date?

Phio Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 70 days.

How were Phio Pharmaceuticals’s earnings last quarter?

Phio Pharmaceuticals released its earnings results on Aug 14, 2025. The company reported -$0.45 earnings per share for the quarter, the consensus estimate of -$0.45 by $0.

Is Phio Pharmaceuticals overvalued?

According to Wall Street analysts Phio Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Phio Pharmaceuticals pay dividends?

Phio Pharmaceuticals does not currently pay dividends.

What is Phio Pharmaceuticals’s EPS estimate?

Phio Pharmaceuticals’s EPS estimate is -0.46.

How many shares outstanding does Phio Pharmaceuticals have?

Phio Pharmaceuticals has 5,726,750 shares outstanding.

What happened to Phio Pharmaceuticals’s price movement after its last earnings report?

Phio Pharmaceuticals reported an EPS of -$0.45 in its last earnings report, expectations of -$0.45. Following the earnings report the stock price went down -0.457%.

Which hedge fund is a major shareholder of Phio Pharmaceuticals?

Currently, no hedge funds are holding shares in PHIO

Company Description

Phio Pharmaceuticals

Phio Pharmaceuticals Corp. is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company specializes in the field of RNA interference (RNAi) and is pioneering the development of self-delivering RNAi (sd-rxRNA) therapeutics aimed at enhancing the efficacy of existing cancer treatments by targeting various pathways involved in tumor growth and immune evasion.

Phio Pharmaceuticals (PHIO) Earnings & Revenues

Historic Earnings Reports

PHIO Stock 12 Month Forecast

Average Price Target

$14.00

▲(589.66% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","22":"$22","33":"$33","44":"$44"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,11,22,33,44],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.33,3.227692307692308,4.125384615384616,5.023076923076923,5.920769230769231,6.818461538461539,7.716153846153846,8.613846153846154,9.51153846153846,10.409230769230769,11.306923076923077,12.204615384615385,13.102307692307692,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.33,3.227692307692308,4.125384615384616,5.023076923076923,5.920769230769231,6.818461538461539,7.716153846153846,8.613846153846154,9.51153846153846,10.409230769230769,11.306923076923077,12.204615384615385,13.102307692307692,{"y":14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.33,3.227692307692308,4.125384615384616,5.023076923076923,5.920769230769231,6.818461538461539,7.716153846153846,8.613846153846154,9.51153846153846,10.409230769230769,11.306923076923077,12.204615384615385,13.102307692307692,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":43.2,"date":1669852800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.18,"date":1672531200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.12,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.48,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.85,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.89,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >